Johnson Laura L. 4
4 · Odonate Therapeutics, Inc. · Filed Dec 10, 2020
Insider Transaction Report
Form 4
Douglass Laura L.
Director
Transactions
- Award
Stock Option (Right to Buy)
2020-12-08+15,000→ 15,000 totalExercise: $16.52Exp: 2030-12-08→ Common Stock (15,000 underlying)
Footnotes (1)
- [F1]The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date.